Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NEUP
NEUPHORIA THERAPEUTICS INC.
NASDAQ
$3.76
▼ DOWN 0.27% (-0.01)

KEY STATISTICS

Market Cap$20.32 M
52w High$21.40
52w Low$3.19
Dividend Yield—
Frequency—
P/E-0.34
Volume29.91K
Shares Out.5.40M

COMPANY

LEADERSHIP

Spyridon Papapetropoulos
CHIEF EXECUTIVE
Spyridon Papapetropoulos

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 16, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
8

PRICE TARGET

Target High$7.00
Target Low$7.00
Target Median$7.00
Target Consensus$7.00

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.—
SEP
2
WED

SPLIT RECORD

DATETYPERATIO
2024-12-24Reverse1:12

PRICE

$3.76 ▼ DOWN 0.27% (−$0.01)
OVERLAYS
$3.76$3.78$3.80$3.829:47 AM10:49 AM11:51 AM12:53 PM1:55 PM2:57 PM3:59 PM3.76

About Neuphoria Therapeutics Inc.

http://www.neuphoriatx.com ↗

Neuphoria Therapeutics, Inc., founded in 2024 and based in Burlington, MA, is a clinical-stage biotech company focused on developing therapies for neuropsychiatric disorders.

INDUSTRY

Biotechnology

A PRODUCT NEUPHORIA THERAPEUTICS INC. IS KNOWN FOR

BNC-210
BNC-210

Neuphoria Therapeutics' BNC-210 is an oral, selective α7 nicotinic receptor modulator developed for neuropsychiatric disorders, with ongoing evaluation for PTSD after a Phase 3 trial for social anxiety disorder did not meet endpoints.

COMPETITORS

COMPETITOR
ATAI COMPARE
CMPS COMPARE
VTGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
2
RANKED BY POSITION SIZE
PSIL
2.02% · 302.8K
VTS.AX
0.00% · 110.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
28.12%
HOLDERS
15
TOP 12 OF 15 · RANKED BY POSITION SIZE
Lynx1 Capital Management LP
875.3K sh · $3.56M
Advisorshares Investments LLC
155.4K sh · $632.34K
Shay Capital LLC
151.0K sh · $614.61K
Balyasny Asset Management L.P.
142.2K sh · $578.68K
Geode Capital Management, LLC
52.0K sh · $211.67K
Ikarian Capital, LLC
47.4K sh · $193.09K
Adar1 Capital Management, LLC
30.0K sh · $122.1K
Citadel Advisors LLC
19.3K sh · $78.68K
Boothbay Fund Management, LLC
14.0K sh · $56.98K
Virtu Financial LLC
12.0K sh · $49K
Commonwealth Equity Services, LLC
11.2K sh · $45.67K
Merck & Co., Inc.
10.0K sh · $40.81K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
DIRECTOR
Wilson David Ian
Purchase · 8.5K shares
2026-01-20
★
DIRECTOR
Davies Peter Miles Winston
Purchase · 8.5K shares
2026-01-20
★
DIRECTOR
Fisher Alan
Purchase · 17.1K shares
2026-01-20
★
DIRECTOR
Ryan Jane
Purchase · 8.5K shares
2026-01-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL Maxim Group BUY

SECTORS PEERS

PEERPRICE
BCDA$1.15COMPARE
LFWD$7.46COMPARE
APRE$0.84COMPARE
BMRA$2.14COMPARE
ALZN$1.66COMPARE
LUCY$0.95COMPARE
PFSA$2.93COMPARE